Drugs / Tesofensine
Tesofensine
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03286829 | Dec 2017 → Feb 2018 | — | Saniona | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00428415 | Mar → Dec 2007 | obesity disorder | NeuroSearch A/S | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT05198362 | Dec 2021 → Dec 2022 | Prader-Willi syndrome | Saniona | Withdrawn | No outcome recorded |
| Phase 2 | NCT05147415 | Nov 2021 → Dec 2022 | acquired hypothalamic obesity | Saniona | Withdrawn | No outcome recorded |
| Phase 2 | NCT03845075 | Feb 2019 → Oct 2020 | acquired hypothalamic obesity | Saniona | Completed | No outcome recorded |
| Phase 2 | NCT03149445 | Mar 2017 → Jul 2019 | Prader-Willi syndrome | Saniona | Completed | No outcome recorded |
| Phase 2 | NCT02737891 | Apr 2016 → Jan 2017 | type 2 diabetes mellitus | Saniona | Completed | No outcome recorded |
| Phase 2 | NCT00481104 | May 2007 → Sep 2008 | obesity disorder | NeuroSearch A/S | Completed | No outcome recorded |
| Phase 2 | NCT00394667 | Sep 2006 → Sep 2007 | obesity disorder | NeuroSearch A/S | Completed | No outcome recorded |
| Phase 2 | NCT00148486 | Jun 2003 → Mar 2005 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00148512 | Mar 2003 → Feb 2005 | Parkinson disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00153010 | Feb 2003 → Mar 2005 | Alzheimer disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00006077 | Aug 2000 → Jul 2003 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tesofensine | “1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50...” NCT03286829 ↗10“This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.” NCT05198362 ↗ “Tesomet (tesofensine + metoprolol)” NCT05147415 ↗ “NS 2330 (Tesofensine)” NCT00153010 ↗ |
| Known as | NS 2330 | “Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.” PMID 18474731 ↗ May 2008 |
| Known as | Tesofensina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989690 ↗ |
| Action | Inhibit | “potent inhibitor of dopamine reuptake” NCT00006077 ↗ |
| Modality | Small molecule | — CHEMBL3989690 ↗ |
| Route | Oral | “Patients will take three pills containing NS2330 or placebo (a look-alike pill with no active ingredient) 3 days a week for up to 5 weeks” NCT00006077 ↗ |